Navigation Links
Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Date:9/10/2007

ety profile of this triplet regimen and to lay the groundwork for a potential larger Phase 2/3 trial. We expect to start our Phase 2 monotherapy trial in newly-diagnosed HER2-positive patients later this year. We believe that the clinical activity of alvespimycin seen in our breast cancer Phase 1 trials to date validates the compound's therapeutic potential as a novel anticancer agent and strengthens Kosan's leadership in the Hsp90 inhibitor area."

Phase 1 Updated Results

Alvespimycin is a second-generation Hsp90 inhibitor that has demonstrated the potential to disrupt the activity of multiple oncogenes and cell signaling pathways implicated in tumor growth, including HER2, a key signaling pathway in breast cancer.

Preliminary results from the Phase 1 trial of alvespimycin in combination with trastuzumab were presented at the 2007 ASCO annual meeting in June, and were updated in this presentation. The Phase 1 trial was designed to identify the recommended Phase 2 dose through the evaluation of toxicity and activity in patients with solid tumors. Patients were enrolled in three dose cohorts. The dosing schedule for alvespimycin was a one-hour weekly intravenous infusion of 60, 80 or 100 mg/m2 administered along with the standard dose of trastuzumab. Patients were assessed every 4 weeks for toxicity and every 8 weeks for response. Disease response was assessed by RECIST and by tumor markers, if available.

Of the 27 heavily-pretreated patients enrolled in the trial, 24 patients had HER2-positive breast cancer (with the majority of patients having had multiple trastuzumab-containing regimens prior to this study) and 3 patients had ovarian cancer (HER2 status unknown).

Clinical benefit was observed in 42% of evaluable patients (8 of 19 evaluable) with HER2-positive metastatic breast cancer:

-- 1 patient (13 prior regimens, including progression on single-agent

lapatinib and 3 prior trastuzumab-containing regimens) showed compl
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
6. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
7. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
8. ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met Inhibitor, for Oral Presentation at ASCO
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gvzjt8/investigation ... on China,s Sodium Ibandronate Market, 2010-2019" report to their ... under the trade name of Bondronat in Germany ... sodium ibandronate was approved by the FDA to come into ... trade name of Boniva. However, since drug makers later developed ...
(Date:9/4/2015)... 4, 2015 Hutchison China ... Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, ... proof-of-concept ("POC") trial of fruquintinib in patients with ... China .  The top-line results ... the primary efficacy endpoint of progression free survival ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... N.J., April 25, 2011 MonoSol Rx, LLC ... technology, today announced that the Company has entered ... a biopharmaceutical company focused on the discovery and ... of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular ...
... SynapDx Corporation announced today that Thomas Mac ... Thomas Mac Mahon was President and Chief Executive Officer and ... Corporation of America (LabCorp) from January 1997 until his retirement ... Mahon was Senior Vice President of Hoffmann-La Roche Inc. (Roche) ...
Cached Medicine Technology:MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD 2MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD 3MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD 4
(Date:9/4/2015)... ... ... With TransCel from Pixel Film Studios users can simulate celluloid media transitions ... users have full control over camera position and angle within 3D space from start ... text, and more. With TransCel the possibilities are endless. , Users have full control ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Providence Fertility Center will ... about their fertility and egg freezing. , Date and Time: October 8, 2015 at ... , This hip and informative event will discuss the basics of female fertility and ...
(Date:9/4/2015)... , ... September 04, 2015 , ... After wearing the ... desperate need of new apparel. In an effort to assist the team, the Jones ... launched a charity drive to raise funds for the new uniforms. , As is ...
(Date:9/4/2015)... ... September 04, 2015 , ... Scalability Experts (SE) ... Year” awards at this year’s Microsoft Worldwide Partner Conference that was held in ... Year” Award Winner for Data Platform services, the 2015 HP and Microsoft “Outstanding ...
(Date:9/4/2015)... ... September 04, 2015 , ... “Getting away from the daily stressors and distractions ... and strengthen their ‘couple-ness,’” says Jean Claude Wietzel, general manager at Four Seasons ... the island’s only Forbes Five Star resort and Travel + Leisure’s No. 1 Hotel ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:The Providence Fertility Center to Host Fertility Cocktail Hour on October 8, 2015 at Waterman Grille for Women Who Wish to Learn About Their Fertility and Egg Freezing 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3
... receive a combination of medication and a psychosocial intervention ... have improved insight, quality of life and social functioningthan ... the September issue of Archives of General Psychiatry ... are the mainstay of therapy for patients with schizophrenia, ...
... one-fifth of fathers in the United Kingdom appear to experience ... year of age, with the highest rates in the first ... that will appear in the November print issue of ... JAMA/Archives journals. "Depression in parents is associated with adverse ...
... (Sept. 3) A long-term study of women with a ... who elected major preventive surgeries had a significantly reduced risk ... the Journal of the American Medical Association, confirms the view ... director of the Greehey Children,s Cancer Research Institute at The ...
... Mass. - Phosphorus, a mineral element found in rocks ... detergents and other industrial and household chemicals. Once phosphorus ... is hazardous and expensive, and chemists have been trying ... professor Christopher Cummins and one of his graduate students, ...
... progression of the giant iceberg that calved from Greenland,s Petermann ... iceberg, the largest in the northern hemisphere, is now entering ... Lincoln Sea and Arctic Ocean with Baffin Bay. The ... of the country,s glaciers and until August it had ...
... Researchers at Queen,s University have found that people with ... without the disease, but have significant difficulty switching from ... towards understanding the aspects of the illness that affect ... "We often think of Parkinson,s disease as being a ...
Cached Medicine News:Health News:Combining medication and psychosocial treatments may benefit patients with early-stage schizophrenia 2Health News:Parents at highest risk for depression in the first year after child's birth 2Health News:For some women, preventive mastectomies pay off 2Health News:MIT moves toward greener chemistry 2Health News:MIT moves toward greener chemistry 3Health News:Earth from space: Giant iceberg enters Nares Strait 2
... OTI's new Spectral system is a combination ... Laser Ophthalmoscope (SLO) system that provides suberb, ... choroidal-retina structure. With the advancements of spectral ... of up to 27,000 A-Scans per second ...
... SC is an ideal gamma ... with the ability to perform ... views, Myocardial perfusion diagnosis and ... low cost and space efficient ...
... Coil is intended for: embolization of those ... their location, or the patient's general medical ... team to be a) very high risk ... b) inoperable.,The GDC is also intended for ...
Designed to have a shock-absorbing force, providing less bounce or wasted force....
Medicine Products: